Alexion Pharmaceuticals Inc $ 110.55 -3.17 (-2.79%)

On watch
Volume:
1,321,737
Avg Vol (1m):
1,951,177
Market Cap $:
24.19 Bil
Enterprise Value $:
23.95 Bil
P/E (TTM):
29.51
P/B:
2.30
Warning! GuruFocus has detected 1 Severe warning sign with ALXN. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 10Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for ALXN (Alexion Pharmaceuticals Inc) from 1996 to Sep 21 2020. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Alexion Pharmaceuticals stock (ALXN) PE ratio as of Sep 21 2020 is 29.51. More Details

Alexion Pharmaceuticals PE Ratio (TTM) Chart

EMBED

Alexion Pharmaceuticals PE Ratio (TTM) Historical Data

Total 1298
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 15
Alexion Pharmaceuticals PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2020-09-2129.6 2020-07-2029.3
2020-09-1830.4 2020-07-1729.2
2020-09-1730.5 2020-07-1629.3
2020-09-1631.2 2020-07-1529.7
2020-09-1530.9 2020-07-1429.0
2020-09-1429.1 2020-07-1328.6
2020-09-1128.2 2020-07-1029.1
2020-09-1028.3 2020-07-0929.0
2020-09-0929.0 2020-07-0828.9
2020-09-0828.9 2020-07-0730.1
2020-09-0730.2 2020-07-0630.4
2020-09-0430.2 2020-07-0330.0
2020-09-0329.8 2020-07-0230.0
2020-09-0230.4 2020-07-0130.1
2020-09-0130.1 2020-06-3030.0
2020-08-3130.5 2020-06-2929.7
2020-08-2828.6 2020-06-2610.7
2020-08-2728.4 2020-06-2510.7
2020-08-2627.9 2020-06-2410.5
2020-08-2527.6 2020-06-2310.9
2020-08-2427.4 2020-06-2211.0
2020-08-2126.9 2020-06-1911.2
2020-08-2027.0 2020-06-1811.0
2020-08-1927.2 2020-06-1710.9
2020-08-1827.6 2020-06-1610.7
2020-08-1727.5 2020-06-1510.4
2020-08-1427.5 2020-06-1210.3
2020-08-1327.2 2020-06-1110.3
2020-08-1227.5 2020-06-1011.0
2020-08-1127.1 2020-06-0910.9
2020-08-1027.2 2020-06-0811.3
2020-08-0727.6 2020-06-0510.9
2020-08-0627.8 2020-06-0410.7
2020-08-0527.5 2020-06-0310.7
2020-08-0428.1 2020-06-0211.0
2020-08-0328.0 2020-06-0111.2
2020-07-3127.4 2020-05-2911.3
2020-07-3028.0 2020-05-2810.8
2020-07-2928.0 2020-05-2710.0
2020-07-2828.1 2020-05-269.7
2020-07-2728.6 2020-05-259.6
2020-07-2427.1 2020-05-229.6
2020-07-2328.0 2020-05-219.5
2020-07-2228.3 2020-05-209.8
2020-07-2128.6 2020-05-199.5

Alexion Pharmaceuticals PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Healthcare » Biotechnology » NAICS : 541714 NAICS : 8731
Address 121 Seaport Boulevard, Boston, MA, USA, 02210
Alexion Pharmaceuticals Inc specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target other ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.